136 related articles for article (PubMed ID: 17686243)
1. [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren Y; Zha X; Zhang GN
Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1204-6. PubMed ID: 17686243
[TBL] [Abstract][Full Text] [Related]
2. [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
Zhang PN; Sun H
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):196-200. PubMed ID: 17537308
[TBL] [Abstract][Full Text] [Related]
3. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
4. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Hu L; Zaloudek C; Mills GB; Gray J; Jaffe RB
Clin Cancer Res; 2000 Mar; 6(3):880-6. PubMed ID: 10741711
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
8. [Influence of human epithelial ovarian cancer HO-8910 cells with modified survivin gene on the cell cycle distribution and chemosensitivity].
Peng LP; Huang JM; Zhang GN; Zha X; Ren Y; Fan Y; Deng BF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):860-4. PubMed ID: 21211287
[TBL] [Abstract][Full Text] [Related]
9. [Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
Xiao L; He C; Li X; Chen Y; Zhou JD
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):616-20. PubMed ID: 23141184
[TBL] [Abstract][Full Text] [Related]
10. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
11. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Lee CM; Fuhrman CB; Planelles V; Peltier MR; Gaffney DK; Soisson AP; Dodson MK; Tolley HD; Green CL; Zempolich KA
Clin Cancer Res; 2006 Jan; 12(1):250-6. PubMed ID: 16397049
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Hu L; Hofmann J; Jaffe RB
Clin Cancer Res; 2005 Nov; 11(22):8208-12. PubMed ID: 16299254
[TBL] [Abstract][Full Text] [Related]
14. [High D-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction].
Yu P; Yu DM; Qi JC; Wang J; Zhang QM; Zhang JY; Tang YZ; Xing QL; Li MZ
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3425-30. PubMed ID: 17313857
[TBL] [Abstract][Full Text] [Related]
15. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
16. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
17. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
18. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
[TBL] [Abstract][Full Text] [Related]
20. [Effect and mechanism of LY294002 on growth of fibrosarcoma cell line HT1080].
Zhou H; Huang XY; Yang T; Wang T; Xu D; Wen FQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 41(1):20-3. PubMed ID: 20369463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
